Amarin Receives National Reimbursement for VAZKEPA® in Italy
Portfolio Pulse from
Amarin Corporation has received national reimbursement approval for its drug VAZKEPA® (icosapent ethyl) in Italy. This approval allows the drug to be reimbursed for reducing cardiovascular risk in eligible high-risk patients. Italy is the third EU5 market to grant such reimbursement, marking the ninth national reimbursement for VAZKEPA® in Europe.
December 16, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amarin Corporation's drug VAZKEPA® has been approved for national reimbursement in Italy, allowing it to be reimbursed for reducing cardiovascular risk in high-risk patients. This is a significant expansion in the European market.
The national reimbursement approval in Italy for VAZKEPA® is a positive development for Amarin, as it expands the drug's market reach in Europe. This approval is likely to increase sales and revenue potential in a significant market, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90